- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04877275
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Selinexor in Combination With Chemotherapy to Treat Relapsed/Refractory Multiple Myeloma Patients
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Chunyan Sun, M.D., Ph.D
- Phone Number: 13237183940
- Email: suncy0618@163.com
Study Contact Backup
- Name: Hongwei Li, MSc
- Phone Number: 18205191049
- Email: cpu_473lhw@126.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Baijun Fang, Ph.D
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- Not yet recruiting
- Zhongnan Hospital of Wuhan University
-
Contact:
- Fuling Zhou, Ph.D
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
-
Contact:
- Chunyan Sun, M.D.,Ph.d
- Phone Number: 13237183940
- Email: suncy0618@163.com
-
Principal Investigator:
- Chunyan Sun, M.D.,Ph.d
-
Principal Investigator:
- Yu Hu, M.D.,Ph.d
-
Sub-Investigator:
- Junying Li, M.D.,Ph.d
-
-
Shanxi
-
Xi'an, Shanxi, China, 710000
- Not yet recruiting
- The First Affiliated Hospital of Air Force Medical University
-
Contact:
- Guangxun Gao, PhD
-
Xi'an, Shanxi, China, 710004
- Not yet recruiting
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Aili He, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
- Known and written informed consent (ICF) voluntarily.
- Age ≥ 18 years and ≤ 75 years.
- Patients with multiple myeloma who have received first-line treatment (induction, autologous transplantation and maintenance as the same first-line treatment) and achieved at least partial remission in induction.
- At or after accepting first-line regimen, subjects must have progression disease (PD) recorded which is determined by researcher according to IMWG criteria.
- Any clinically significant non-hematological toxicities (except for hair loss, peripheral neuropathy, which is otherwise stipulated in Article 13 of the exclusion criteria) that relevant to previous therapies must have resolved to ≤Grade 2 prior to first dose of study drug.
- Left ventricular ejection fraction(LVEF )≥50% by an echocardiogram or MUGA scan in 42 days before the first administration
- Adequate hepatic function: total bilirubin < 2× upper limit of normal (ULN) (for patients with Gilbert's syndrome, a total bilirubin of < 3× ULN is required), AST < 2.5× ULN, and ALT < 2.5× ULN.
- Adequate renal function: estimated creatinine clearance ≥ 20 mL/min (calculated using the formula of Cockroft-Gault).
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
Measurable MM as defined by at least one of the following:
- Serum M-protein (SPEP) ≥ 5 g/L
- 24 hours-Urinary M-protein excretion ≥ 0.2 g (200 mg)
- Serum FLC ≥ 100 mg/L with abnormal FLC ratio
- Expected survival is more than 6 months.
Adequate hematopoietic function (no platelet transfusion within 2 weeks prior to screening test):
- Hemoglobin level ≥ 60 g/L
- ANC ≥ 1,000/mm3 (1.0×109/L)
- Platelet count ≥ 75,000/mm3 (75×109/L)
Female patients of childbearing potential must meet below two criteria:
- must agree to use effective contraception methods since signature in ICF, throughout the study and for 3 months following the last dose of study treatment.
- must have a negative serum pregnancy test at screening. Note: A woman is considered of childbearing potential following menarche and until becoming postmenopausal (defined as no menstrual period for a minimum of 12 months) or permanently sterile (having undergone a hysterectomy, bilateral salpingectomy or bilateral oophorectomy). A woman who is taking oral contraceptive or using intrauterine device is considered of childbearing potential.
- Male patients (including those who have received vasectomy) must use a condom if sexually active with a female of child-bearing potential throughout the study and for 3 months following the last dose of study treatment.
Exclusion Criteria:
Patients who meet any of the following criteria will not be enrolled:
- Asymptomatic (smoldering) MM.
- Plasma cell leukemia.
- Documented active amyloidosis.
- Previously refractory or intolerant to combined drugs.
- Pregnancy or breastfeeding.
- Major surgery was performed within 4 weeks prior to the first study.
Patients with active, unstable cardiovascular diseases, fits any of the following:
- Symptomatic ischemia, or
- Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with first-degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) are allowed), or
- Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3, or
- Acute myocardial infarction (AMI) within 3 months prior to the first dose of study drug.
- Uncontrolled active infection within 1 week prior to the first dose of study drug.
- Known HIV positive.
Known active hepatitis A, B, or C infection; or known positive for HCV RNA or HBsAg.
(Note: patients with HBsAg negative but HBc Ab positive need further HBV-DNA test, excluded if HBV-DNA ≥103 , if HBV-DNA <103 need anti-viral drugs)
- Prior malignancy that required treatment or has shown evidence of recurrence (except for skin basal-cell carcinoma and in-situ carcinoma including squamous cell carcinoma, bladder cancer in situ, endometrial cancer in situ, cervical cancer in situ/atypical hyperplasia, prostate cancer incidental finding (T1a or T1b), or breast cancer in situ) within 5 years prior to the first dose of study drug.
- Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that could interfere with absorption of study treatment.
- Grade ≥ 3 peripheral neuropathy, and Grade ≥ 2 painful neuropathy, within 3 weeks prior to the first dose of study drug.
- Serious, active psychiatric, or medical conditions which, in the opinion of the Investigator, could interfere with study treatment.
- Participation in an investigational anti-cancer clinical study within 3 weeks or 5 half-lives (T1/2) prior to the first dose of study drug.
- Received ASCT within 12 weeks prior to the first dose of study drug or previous allogeneic stem cell transplantation (no time limitation).
- Treatment with an approved or trial anticancer drug was given within 3 weeks or 5 half-lives (T1/2) (With a short time priority) prior to the first study.
- Prior exposure to a SINE compound.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I: Selinexor+Pegylated liposomal doxorubicin +Dexamethasone
Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects.
4 weeks per cycle and include a total of 12 cycles.
|
Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Arm I:80mg/d QW ;
Other Names:
25 mg/m^2 intravenously on day 1 , QW
Other Names:
Dexamethasone 40mg/d QW
Other Names:
|
Experimental: Arm II: Selinexor+Cyclophosphamide+Dexamethasone
Arm II is given XCd regimen (ATG-010 100mg/d QW, Cyclophosphamide 300mg/m2, d1and Dexamethasone 40mg/d QW). 4 weeks per cycle and include a total of 12 cycles.
|
Dexamethasone 40mg/d QW
Other Names:
Selinexor (ATG-010) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Arm II:100mg/d QW ;
Other Names:
Cyclophosphamide:300mg/m2, d1 QW,
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Assessed from the date of first dose of study treatment until the date that PD assessed up to 12months
|
ORR in each arm: partial response (PR) + very good partial response (VGPR) + complete response (CR)
|
Assessed from the date of first dose of study treatment until the date that PD assessed up to 12months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: 12 months
|
Duration from start of study treatment to PD or death (regardless of cause), whichever comes first
|
12 months
|
Clinical Benefit Rate (CBR)
Time Frame: 12 months
|
Clinical Benefit Rate (CBR=ORR+Minor Response [MR])
|
12 months
|
Disease Control Rate (DCR)
Time Frame: 12 months
|
Disease Control Rate (DCR=CBR+Stable Disease[SD; for a minimum of 12 weeks])
|
12 months
|
Number of Participants with Adverse Events
Time Frame: From first dose of study drug administration to end of treatment (up to 12 months)
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
|
From first dose of study drug administration to end of treatment (up to 12 months)
|
Overall Survival (OS)
Time Frame: 12 months
|
The estimates of Kaplan-Meier
|
12 months
|
Minimal Residual Disease (MRD)
Time Frame: 12 months
|
To evaluate the minimal residual disease in CR and sCR patients
|
12 months
|
Duration of Response (DOR)
Time Frame: 12 months
|
Duration from the first observation of at least PR to time of disease progression, or deaths due to disease progression, whichever occurs first.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chunyan Sun, M.D., Ph.D, Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Dexamethasone
- Cyclophosphamide
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- ATG-010-IIT-MM-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Selinexor (80mg/d)
-
Karyopharm Therapeutics IncBelgium and Luxembourg Gynaecological Oncology Group; North-Eastern German... and other collaboratorsActive, not recruitingEndometrial CancerUnited States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Rhabdoid Tumor | Wilms Tumor | Nephroblastoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | XPO1 Gene MutationUnited States
-
The First Hospital of Jilin UniversityRecruitingPTCL Patients Who Achieved Complete Response From Frontline TreatmentChina
-
University of RochesterKaryopharm Therapeutics IncRecruitingSmoldering Multiple MyelomaUnited States
-
Karyopharm Therapeutics IncGOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaboratorsRecruitingEndometrial CancerUnited States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Slovakia, Canada, Hungary, Czechia
-
GenfitCompletedType II Diabetes MellitusBosnia and Herzegovina, Latvia, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Serbia
-
University of UtahKaryopharm Therapeutics IncActive, not recruitingPrimary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States
-
Nanjing Zenshine PharmaceuticalsNot yet recruiting
-
GenfitCompletedImpaired Glucose Tolerance | Abdominal ObesityFrance
-
Karyopharm Therapeutics IncCompletedHematological MalignanciesUnited States, Denmark, Canada